Search company, investor...

Predictive Biosciences

Founded Year



Dead | Dead

Total Raised


About Predictive Biosciences

Predictive Biosciences is an early stage developer of intervention diagnostic assays for oncology management.

Headquarters Location

128 Spring Street 400 Level, B Annex

Lexington, Massachusetts, 02421,

United States


Missing: Predictive Biosciences's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Predictive Biosciences's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Predictive Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Predictive Biosciences is included in 1 Expert Collection, including Cancer.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Predictive Biosciences Patents

Predictive Biosciences has filed 7 patents.

patents chart

Application Date

Grant Date


Related Topics




Molecular biology, Molecular biology techniques, Biotechnology, Proteins, Posttranslational modification


Application Date


Grant Date



Related Topics

Molecular biology, Molecular biology techniques, Biotechnology, Proteins, Posttranslational modification



Latest Predictive Biosciences News

In Brief This Week: Physician’s Laboratory Choice Services, Predictive Biosciences; Microsaic Systems; Protea Biosciences

Apr 18, 2014

In Nature this week: Down's syndrome analysis, and more. Papers of Note McFadden, Papagiannakopoulos, et al. Cell A genome sequencing study by researchers from Massachusetts provides a peek at the processes behind small-cell lung carcinoma development and progression. The team developed a genetically engineered mouse model of the small-cell lung carcinoma missing two of the genes that have previously been shown to be oft-mutated in human forms of the disease. By sequencing the genomes or exomes of primary or metastatic tumors that developed in six of the mice, together with matched normal tissue sample, the investigators narrowed in on recurrent copy number changes, rearrangements, and somatic mutations in the mouse models of small-cell lung carcinoma. They also tracked down patterns associated with metastasis, including sequential alterations in tumors that spread to other parts of the body. RNA editome in rhesus macaque shaped by purifying selection Chen, Peng, et al. PLOS Genetics A Peking University-led team describes RNA editing patterns they detected by sequencing DNA and RNA from multiple rhesus macaque tissues. Using data from one rhesus macaque, the researchers narrowed in on some 31,250 examples of RNA editing. Most of those appeared to be adenine to guanine swaps, they note, apparently due to adenosine deamination. "[T]he macaque editome reported here highlights RNA editing as a widespread functional regulation in primate evolution," they conclude, "and provides an informative framework for further understanding RNA editing in human. " People on the Move CollabRx has appointed Paul Billings to its board of directors. Billings is a board certified internist and clinical geneticist and most recently served as chief medical officer for Life Technologies. He is executive chairman of Melanoma Diagnostics, a director of Trovagene, and a co-founder and past medical director of the Cordblood Registry. He was also a senior vice president for corporate development at Laboratory Corporation of America and a co-founder of Omicia. Billings also currently serves on the Scientific Advisory Board of the US Food and Drug Administration, the Genomic Medicine Advisory Committee at the Department of Veterans Affairs, and the National Academy of Sciences Institute of Medicine’s Roundtable on Genomics. Kathy Hibbs, former senior VP and general counsel at Genomic Health, has joined 23andMe as chief legal and regulatory officer. Hibbs joins 23andMe while the firm is in the midst of regulatory discussions with the US Food and Drug Administration regarding its Personal Genome Service. Hibbs has also worked at Monogram Biosciences and Varian Medical Systems, and is actively engaged in a number of industry groups, such as the American Clinical Laboratory Association, the Coalition for 21st Century Medicine, and the Personalized Medicine Coalition. Stephen Rusckowski has been named chairman of the American Clinical Laboratory Association's board of directors. Rusckowski has served as Quest Diagnostics' president and CEO since May 2012. Before joining Quest Diagnostics he was CEO of Philips Healthcare. ProteinSimple has appointed Joe Keegan and Chris van Ingen to its board of directors. Keegan was previously the CEO of ForteBio and Molecular Devices. Van Ingen was previously president of Agilent Technologies' bio-analytical measurement business. He currently serves on the boards of Bruker, Accelrys, and Promega. Upcoming Events

Predictive Biosciences Frequently Asked Questions (FAQ)

  • When was Predictive Biosciences founded?

    Predictive Biosciences was founded in 2006.

  • Where is Predictive Biosciences's headquarters?

    Predictive Biosciences's headquarters is located at 128 Spring Street, Lexington.

  • What is Predictive Biosciences's latest funding round?

    Predictive Biosciences's latest funding round is Dead.

  • How much did Predictive Biosciences raise?

    Predictive Biosciences raised a total of $56.75M.

  • Who are the investors of Predictive Biosciences?

    Investors of Predictive Biosciences include Flybridge Capital Partners, Highland Capital Partners, New Enterprise Associates, Kaiser Permanente Ventures and ProQuest Investments.

  • Who are Predictive Biosciences's competitors?

    Competitors of Predictive Biosciences include Linkage Biosciences, Biocept, Aviir, VitaPath Genetics, Nodality and 9 more.

Compare Predictive Biosciences to Competitors

Columbia BioSystems

Columbia BioSystems Inc. is a company engaged in molecular Nano-diagnostics using Molecularly Imprinted Polymers (MIPs) for the rapid detection of pathogens such as Methicillin-resistant Staphylococcus aureus (MRSA) , Anthrax, HIV, and Trypanosomiasis (sleeping sickness). The company uses MIPs to bind to proteins and, upon binding, change color thereby signaling the presence of the bacteria, virus or parasite.


JJET is committed to the development, production, and sales of products in the field of electrophysiology; the products mainly include a three-dimensional cardiac mapping system, multi-channel physiological recorder, cardiac electrophysiological stimulator, cardiac radiofrequency ablation device, cold saline perfusion pump, cardiac electrophysiological mapping catheter, cardiac radiofrequency ablation catheter, nerve radiofrequency treatment instrument. The company was founded in 1991 and is based in Chengdu, China.


Immutell aims to develop, produce and market Cell Mediated Immune Response diagnostics to help combat diseases that are difficult to diagnose.

MetaMol Theranostics

MetaMol aims to develop diagnostics for the ability of cancer to spread and to supplement existing cancer therapies with anti-metastasis drugs.


Litholink offers metabolic evaluations for kidney stone formers.


AllerQuest was established by a team including Emeritus Professor Charlotte Ressler, specifically to further develop and produce skin test reagents to safely and accurately identify patients who are at risk for potentially life threatening reactions to penicillin antibiotics. The firm has developed a GMP facility in Plainville to support production and sales of their first product Pre-Pen. (Graduated from incubator)

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.